SG11201608064WA - Compositions and methods for treating neurodegenerative diseases - Google Patents
Compositions and methods for treating neurodegenerative diseasesInfo
- Publication number
- SG11201608064WA SG11201608064WA SG11201608064WA SG11201608064WA SG11201608064WA SG 11201608064W A SG11201608064W A SG 11201608064WA SG 11201608064W A SG11201608064W A SG 11201608064WA SG 11201608064W A SG11201608064W A SG 11201608064WA SG 11201608064W A SG11201608064W A SG 11201608064WA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- neurodegenerative diseases
- treating neurodegenerative
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461971862P | 2014-03-28 | 2014-03-28 | |
PCT/US2015/023060 WO2015148962A1 (en) | 2014-03-28 | 2015-03-27 | Compositions and methods for treating neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201608064WA true SG11201608064WA (en) | 2016-10-28 |
Family
ID=54196457
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202001065SA SG10202001065SA (en) | 2014-03-28 | 2015-03-27 | Compositions and methods for treating neurodegenerative diseases |
SG11201608064WA SG11201608064WA (en) | 2014-03-28 | 2015-03-27 | Compositions and methods for treating neurodegenerative diseases |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202001065SA SG10202001065SA (en) | 2014-03-28 | 2015-03-27 | Compositions and methods for treating neurodegenerative diseases |
Country Status (22)
Country | Link |
---|---|
US (4) | US9802925B2 (en) |
EP (1) | EP3122743B1 (en) |
JP (2) | JP7255967B2 (en) |
KR (2) | KR20160130853A (en) |
CN (3) | CN116139282A (en) |
AU (2) | AU2015237253B2 (en) |
BR (1) | BR112016022575A2 (en) |
CA (1) | CA2944211C (en) |
DK (1) | DK3122743T3 (en) |
ES (1) | ES2939959T3 (en) |
FI (1) | FI3122743T3 (en) |
IL (1) | IL248074B (en) |
MX (2) | MX2016012645A (en) |
MY (1) | MY184878A (en) |
NZ (1) | NZ724718A (en) |
PL (1) | PL3122743T3 (en) |
RU (1) | RU2742773C2 (en) |
SG (2) | SG10202001065SA (en) |
SI (1) | SI3122743T1 (en) |
TW (1) | TWI736519B (en) |
WO (1) | WO2015148962A1 (en) |
ZA (1) | ZA201606673B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012003436A1 (en) | 2010-07-01 | 2012-01-05 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
BR112016022575A2 (en) | 2014-03-28 | 2017-08-15 | Azevan Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
TWI622380B (en) * | 2017-01-17 | 2018-05-01 | 正崴精密工業股份有限公司 | Physiological Signal Measuring Device and Blood Oxygen Calculation Method |
JP2020534274A (en) | 2017-09-15 | 2020-11-26 | アゼヴァン ファーマシューティカルズ,インコーポレイテッド | Compositions and Methods for Treating Brain Injury |
CN116685313A (en) * | 2020-12-23 | 2023-09-01 | 细胞基因公司 | Indanyl-containing carboxylic acid compounds for the treatment of neurodegenerative diseases |
WO2023164710A1 (en) * | 2022-02-28 | 2023-08-31 | The Trustees Of Columbia University In The City Of New York | Avpr1a blockade to reduce social isolation-induced anxiety in females |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
US4314081A (en) | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
NL7503310A (en) | 1975-03-20 | 1976-09-22 | Philips Nv | CONNECTIONS WITH ANTIDEPRESSIVE ACTION. |
US4576753A (en) | 1975-10-06 | 1986-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Azetidinone compounds and processes for preparation thereof |
GB1526331A (en) | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
US4341698A (en) | 1979-06-21 | 1982-07-27 | Richardson-Merrell Inc. | Enkaphalin derivatives |
US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
JPS6033439B2 (en) | 1980-03-07 | 1985-08-02 | 財団法人相模中央化学研究所 | Method for producing dipeptide |
JPS56125361A (en) | 1980-03-07 | 1981-10-01 | Sagami Chem Res Center | Azetidinone compound |
FR2508035A1 (en) | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | ARYL-1-AMINOMETHYL-2 CYCLOPROPANES CARBOXAMIDE (Z) DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS |
US4761501A (en) | 1983-10-26 | 1988-08-02 | American Home Products Corporation | Substituted phenylacetamides |
US4751299A (en) | 1983-11-18 | 1988-06-14 | Takeda Chemical Industries, Ltd. | Optically active β-lactams and method of their production |
US4665171A (en) | 1985-07-17 | 1987-05-12 | Harvard University | Process and intermediates for β-lactam antibiotics |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4734498A (en) | 1986-07-10 | 1988-03-29 | Eli Lilly And Company | 3β-succinimidoazetidinones as chiral intermediates |
US4772694A (en) | 1986-07-24 | 1988-09-20 | Eli Lilly And Company | Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates |
US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
WO1992005784A1 (en) | 1990-10-02 | 1992-04-16 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists |
GB9204001D0 (en) | 1992-02-25 | 1992-04-08 | Jacobs Suchard Ag | Process for producing reduced fat nuts |
US5246943A (en) | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
AU4713293A (en) | 1992-07-13 | 1994-01-31 | Merck Sharp & Dohme Limited | Heterocyclic amide derivatives as tachykinin derivatives |
CA2140640A1 (en) | 1992-08-13 | 1994-03-03 | David C. Horwell | Tachykinin antagonists |
FR2696178B1 (en) | 1992-09-30 | 1994-12-30 | Sanofi Elf | Quaternary basic amides, process for their preparation and pharmaceutical compositions containing them. |
HU224496B1 (en) | 1993-05-06 | 2005-10-28 | Merrel Dow Pharmaceuticals Inc. | Substituted pyrrolidin-3-yl-alkyl-piperidines and pharmaceutical compositions containing them |
US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5759865A (en) | 1995-05-03 | 1998-06-02 | Eli Lilly And Company | Combinatorial process for synthesizing azetidinone analogs |
GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
AU1977997A (en) | 1996-02-23 | 1997-09-10 | Eli Lilly And Company | Non-peptidyl vasopressin v1a antagonists |
WO1999006409A1 (en) | 1997-07-30 | 1999-02-11 | American Home Products Corporation | Tricyclic vasopressin agonists |
US6403632B1 (en) | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
RU2235094C2 (en) | 1997-10-27 | 2004-08-27 | Др. Редди`З Лабораториз Лимитед | Beta-aryl-alpha-hydroxy-substituted alkylcarboxylic acids, methods for their preparing, intermediate compounds, methods for their preparing, pharmaceutical composition, methods for treatment or prophylaxis of diseases based on new compounds |
BR0013366A (en) | 1999-08-16 | 2002-07-23 | Revaax Pharmaceuticals Llc | Methods to treat a behavioral disorder, a human patient, prostate disease, anxiety and cognitive disorders in a human patient afflicted with a condition or willing to develop a condition distinguished at least in part by the concentration of abnormal extracellular glutamate in the brain or in other nervous tissue, behavioral disorder in human, canine, feline and equine species and a patient afflicted with or willing to develop a disease comprising abnormally high glutamate concentrations in neuronal tissue or elevated naaladase levels in prostate tissue and with multiple sclerosis and to enhance cognitive function, pharmaceutical formulation and uses of an inhibitor of peptidase activity of an acidic dipeptidase bound in n-acetylated alpha and a beta-lactam compound |
GB0019006D0 (en) | 2000-08-04 | 2000-09-20 | Astrazeneca Ab | Novel compounds |
MXPA04003358A (en) | 2001-10-12 | 2004-07-08 | Serenix Pharmaceuticals Llc | beta-LACTAMYL VASOPRESSIN Vla. |
AU2002359761A1 (en) | 2001-12-18 | 2003-06-30 | Invenux, Inc. | Antibiotic compounds |
US7135479B2 (en) | 2002-09-12 | 2006-11-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans |
GB0224919D0 (en) * | 2002-10-25 | 2002-12-04 | Pfizer Ltd | Triazole compounds useful in therapy |
KR20060056944A (en) | 2003-07-14 | 2006-05-25 | 아레나 파마슈티칼스, 인크. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
WO2005035492A1 (en) | 2003-10-03 | 2005-04-21 | Serenix Pharmaceuticals, Llc. | 3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS |
US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
EP1632494A1 (en) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
EP1669776A1 (en) | 2004-12-11 | 2006-06-14 | Leica Geosystems AG | Handheld distance measuring apparatus and a method therefore |
FR2881744B1 (en) | 2005-02-09 | 2007-04-27 | Sanofi Aventis Sa | N - [(4,5-DIPHENYL-2-THIENYL) METHYL] AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
JP2008534504A (en) * | 2005-03-22 | 2008-08-28 | アゼヴァン ファーマスーティカルズ,インコーポレイテッド | Β-Lactamyl alkanoic acid for treating premenstrual disorders |
CA2608718A1 (en) * | 2005-05-18 | 2006-11-23 | Pfizer Limited | 1, 2, 4-triazole derivatives as vasopressin antagonists |
SI1910346T1 (en) * | 2005-07-19 | 2019-08-30 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonist |
WO2007109615A2 (en) * | 2006-03-21 | 2007-09-27 | Azevan Pharmaceuticals, Inc. | β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS |
WO2008034032A2 (en) | 2006-09-14 | 2008-03-20 | Azevan Pharmaceuticals, Inc. | Beta-lactam cannabinoid receptor modulators |
CN101541807A (en) | 2006-09-22 | 2009-09-23 | 詹森药业有限公司 | Spiro benzazepines as vasopressin antagonists |
CN101679405A (en) | 2007-03-23 | 2010-03-24 | 阵列生物制药公司 | 2-aminopyridine analogs as glucokinase activators |
FR2927625B1 (en) * | 2008-02-19 | 2010-03-12 | Sanofi Aventis | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
FR2930249B1 (en) | 2008-04-21 | 2010-05-14 | Sanofi Aventis | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
WO2012003436A1 (en) | 2010-07-01 | 2012-01-05 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
CN105263910A (en) | 2013-02-18 | 2016-01-20 | 斯克利普斯研究所 | Modulators of vasopressin receptors with therapeutic potential |
BR112016022575A2 (en) | 2014-03-28 | 2017-08-15 | Azevan Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
JP2020534274A (en) | 2017-09-15 | 2020-11-26 | アゼヴァン ファーマシューティカルズ,インコーポレイテッド | Compositions and Methods for Treating Brain Injury |
-
2015
- 2015-03-27 BR BR112016022575A patent/BR112016022575A2/en not_active Application Discontinuation
- 2015-03-27 RU RU2016138349A patent/RU2742773C2/en active
- 2015-03-27 CN CN202310338451.5A patent/CN116139282A/en active Pending
- 2015-03-27 WO PCT/US2015/023060 patent/WO2015148962A1/en active Application Filing
- 2015-03-27 NZ NZ724718A patent/NZ724718A/en unknown
- 2015-03-27 MX MX2016012645A patent/MX2016012645A/en unknown
- 2015-03-27 US US15/129,190 patent/US9802925B2/en active Active
- 2015-03-27 CA CA2944211A patent/CA2944211C/en active Active
- 2015-03-27 SI SI201531921T patent/SI3122743T1/en unknown
- 2015-03-27 FI FIEP15769990.1T patent/FI3122743T3/en active
- 2015-03-27 DK DK15769990.1T patent/DK3122743T3/en active
- 2015-03-27 KR KR1020167028877A patent/KR20160130853A/en active Application Filing
- 2015-03-27 CN CN202310338535.9A patent/CN116327950A/en active Pending
- 2015-03-27 MX MX2021005502A patent/MX2021005502A/en unknown
- 2015-03-27 SG SG10202001065SA patent/SG10202001065SA/en unknown
- 2015-03-27 CN CN201580027324.7A patent/CN106459021B/en active Active
- 2015-03-27 KR KR1020227038057A patent/KR20220151037A/en not_active Application Discontinuation
- 2015-03-27 EP EP15769990.1A patent/EP3122743B1/en active Active
- 2015-03-27 PL PL15769990.1T patent/PL3122743T3/en unknown
- 2015-03-27 JP JP2017502942A patent/JP7255967B2/en active Active
- 2015-03-27 AU AU2015237253A patent/AU2015237253B2/en active Active
- 2015-03-27 MY MYPI2016703577A patent/MY184878A/en unknown
- 2015-03-27 ES ES15769990T patent/ES2939959T3/en active Active
- 2015-03-27 SG SG11201608064WA patent/SG11201608064WA/en unknown
- 2015-03-30 TW TW104110388A patent/TWI736519B/en active
-
2016
- 2016-09-27 ZA ZA2016/06673A patent/ZA201606673B/en unknown
- 2016-09-27 IL IL248074A patent/IL248074B/en active IP Right Grant
-
2017
- 2017-10-18 US US15/786,772 patent/US10364236B2/en active Active
-
2019
- 2019-06-10 US US16/436,350 patent/US11319306B2/en active Active
- 2019-10-23 AU AU2019253831A patent/AU2019253831B2/en active Active
-
2022
- 2022-04-29 US US17/732,631 patent/US20230123729A1/en active Pending
- 2022-05-09 JP JP2022077195A patent/JP2022116001A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1225651A1 (en) | Isoindoline compositions and methods for treating neurodegenerative disease | |
HK1232141A1 (en) | Methods and compositions for treating huntingtons disease | |
SG11201705093UA (en) | Composition for treating il-6-related diseases | |
IL255421A0 (en) | Compositions and methods of treating a neurodegenerative disease | |
IL246791A0 (en) | Compositions and methods for treating ocular diseases | |
EP2953950A4 (en) | Compositions and methods for treating neurodegenerative diseases | |
RS61929B1 (en) | Methods and compositions for treating cancer | |
IL247699A0 (en) | Compositions and methods for treating kidney disorders | |
EP3139928A4 (en) | Anordrin compositions and methods for treating diseases | |
HUE054204T2 (en) | Compositions and methods for treating and preventing inflammation | |
IL249098A0 (en) | Methods and compositions for treating allergy and inflammatory diseases | |
EP3110446A4 (en) | Methods and compositions for treating siglec-8 associated diseases | |
HK1245127A1 (en) | Methods and compositions for treating brain diseases | |
ZA201606199B (en) | Compositions and methods for treating diabetes and liver diseases | |
ZA201606673B (en) | Compositions and methods for treating neurodegenerative diseases | |
EP3164132A4 (en) | Methods and compositions for treating diseases and conditions | |
ZA201605109B (en) | Compositions and methods for treating neutropenia | |
HK1246206A1 (en) | Compositions and methods for treating glaucoma | |
EP3107534A4 (en) | Compositions and methods for the treatment of neurodegenerative diseases | |
EP3364965A4 (en) | Methods and compositions for treating neurodegenerative diseases | |
HK1244782A1 (en) | Compositions and methods for treating diseases and conditions | |
GB201420348D0 (en) | Compounds for treating neurodegenerative diseases | |
TWI839623B (en) | Compositions and methods for treating neurodegenerative diseases | |
GB201521083D0 (en) | Compositions for treatment and methods thereof | |
GB201419559D0 (en) | Therapeutic compositions and methods |